In the latest issue of Blood, a group from China reported results from a Phase I clinical study which utilized a fully human anti-BCMA CAR (CT103A) to treat 18 relapse/refractory MM patients.5 Compared with other BCMA CARs reports where overall response rate (ORR) was 78% to 89% with a 32% to 53% of complete remission (CR),6 CT103A achieved an ORR of 100%, with 72.2% of patients reaching CR or stringent CR (sCR), and 88.9% achieved very good partial response (VGPR) or better. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.